Compare AbCellera Biologics Inc (ABCL) vs Expedia Group Inc (EXPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Expedia Group Inc — how do they compare? AbCellera Biologics Inc trades at $9.13 (market cap $2.99B), while Expedia Group Inc trades at $321 (market cap $38.53B). The key difference: Expedia Group Inc is far larger — about 12.9× AbCellera Biologics Inc's market cap, and Expedia Group Inc pays a 0.6% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | EXPE | |
|---|---|---|
Market Cap | $2.99B | $38.53B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $321.07 |
52-Week Low | $2.78 | $188.51 |
Enterprise Value | $2.58B | $37.09B |
Dividend Yield | — | 0.6% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
